Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Patent
1995-06-07
1998-10-13
Scheiner, Toni R.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
4353431, 4353432, 4353201, 4241331, 4241341, 4241351, 4241431, 4241441, 4241541, 4241531, 4241521, 4241781, 4241881, 4241831, 5303873, 5303881, 53038822, 5303887, 5303917, 5303913, 536 2353, 536 231, C07H 2104, A61K 39395, C07K 1623, C07K 14725
Patent
active
058211233
ABSTRACT:
Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.
REFERENCES:
patent: 4391904 (1983-07-01), Litman et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4853871 (1989-08-01), Pantoliano et al.
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5101025 (1992-03-01), Piatak, Jr. et al.
patent: 5225539 (1993-07-01), Winter
patent: 5585089 (1996-12-01), Queen et al.
Ahmed, BioEssay, 6(4): 175-177 "Structure and Function of Chimaeric Antibodies".
Alegre et al., J. Immunol., 148(11): 3461-3468 (1992) "Effect of a Single Amino Acid Mutation on the Activating and Immunosuppressive Properties of a Humanized OKT3 Monoclonal Antibody".
Antin, et al., Blood, 78(8): 2139-2149 (1991) "Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies".
Barry, Dermatological Formulations p. 181 (1983) "Percutaneous Absorption".
Better, et al., Science, 240: 1041-1043 (1988) "Escherichia coli Secretion of an Active Chimeric Antibody Fragment".
Better et al., J. Biol. Chem., 267(23): 16712-16718 (1992) "Activity of Recombinant Mitogillin and Mitogillin Immunoconjugates".
Better et al., Proc Natl. Acad. Sci. USA, 90: 457-461 (1993) "Potent Anti-CD5 Ricin A Chain Immunoconjugates from Bacterially Produced Fab' and F(ab')2".
Bird et al., Science, 242: 423-426 (1988) "Single-Chain Antigen-Binding Proteins".
Bolt et al., Eur. J. Immunol, 23(2): 403-411 (1993) "The Generation of a Humanized, Non-Mitogenic CD3 Monoclonal Antibody Which Retains In Vitro Immunosuppressive Properties".
Borrebaeck et al., Bio/Technology, "Kinetic Analysis of Recombinant Antibody-Antigen Interactions: Relation Between Structural Domains and Antigen Binding" 10(6):697-698.
Boulianne et al., Nature, 312: 643-646 (1984) "Production of Fuctional Chimeric Mouse/Human Antibody".
Brady et al., J. Mol. Biol., 227: 253-264 (1992) "Crystal Structure of a Chimeric Fab' Fragment of an Antibody Binding Tumour Cells".
Brown et al., Proc. Natl. Acad. Sci. USA, 88: 2663-2667 (1991) "Anti-Tac-H, a Humanized Antibody To The Interleukin 2 Receptor, Prolongs Primate Cardiac Allograft Survival".
Bruggemann et al., J. Exp. Med., 170: 2153-2157 (1989) "The Immunogenicity of Chimeric Antibodies".
Buchner et al., Biotechnology, 9: 157-162 (1991) "Renaturation, Purification and Characterization of Recombinant F.sub.ab -Fragments Produced in Escherichia Coli".
Byers et al., Blood, 75(7): 1426-1432 (1990) "Use of An Anti-Pan T-Lymphocyte Ricin A Chain Immunotoxin in Steriod-Resistant Acute Graft-Versus-Host Disease".
Caron et al., Cancer Res., 52(24): 6761-6767 (1992) "Biological and Immunological Features of Humanized Mi95 (Anti-CD33) Monoclonal Antibodies".
Carter et al., Proc. Natl. Acad. Sci. USA, 89: 4285-4289 (1992) "Humanization of Anti-p185.sup.HER2 Antibody for Human Cancer Therapy".
Case et al., Proc. Natl. Acad. Sci. USA, 86: 287-291 (1989) "Chimeric Cytotoxin IL2-PE40 Delays and Mitigates Adjuvant-Induced Arthritis in Rats".
Cheadle et al., Mol. Immunol., 29: 21-30 (1992) "Cloning and Expression of the Variable Regions of Mouse Myeloma Protein MOPC315 in E. Coli: Recovery of Active F.sub.v Fragments".
Chothia et al., The EMBO Journal, 7(12): 3745-3755 (1988) "The Outline Structure of the T-Cell .alpha..beta. Receptor".
Chothia et al., J. Mol. Biol., 196: 901-917 (1987) "Canonical Structures for the Hypervariable Regions of Immunoglobulins".
Chothia et al., Nature, 342: 877-883 (1989) "Conformations of Immunoglobulin Hypervariable Regions".
Chothia et al., J. Mol. Biol., 186: 651-663 (1985) "Domain Association in Immunoglobulin Molecules, The Packing of Variable Domains".
Chothia and Lesk, Cold Spring Harbor Symp. Quant. Biol., 52: 399-405 (1987) "The Evolution of Protein Structures".
Choy et al., Scandinavian J. Immunol., 36: 291-298 (1992) "Treatment of Rheumatoid Arthritis With Single Dose or Weekly Pulses of Chimaeric Anti-CD4 Monoclonal Antibody".
Co et al., Nature, 351: 501-502 (1991) "Humanized Antibodies for Therapy".
Co et al., Proc. Natl. Acad. Sci. USA, 88: 2869-2873 (1991) "Humanized Antibodies for Antiviral Therapy".
Co et al., J. Immunol., 148: 1149-1154 (1992) "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen".
Daugherty, et al., Nucleic Acids Res., 19: 2471-2476 (1991) "Polymerase Chain Reaction Facilitates the Cloning, CDR-grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins".
Davies & Metzger, Ann. Rev. Immunol., 1: 87-117 (1983) "Structural Basis of Antibody Function".
Davies and Padlan, Ann. Rev. Biochem., 59: 439-473 (1990) "Antibody-Antigen Complexes".
Derocq et al., Transplantation, 44(6): 763-769 (1987) "Rationale for the Selection of Ricin A-Chain Anti-T Immunotoxins for Mature T Cell Depletion".
Eigenbrot et al., J. Mol. Biol., 229: 969-995 (1993) "X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized Anti-p185.sup.HER3 Antibody 4D5 and Comparison with Molecular Modeling".
Ey et al., Immunochem., 15: 429-436 (1978) "Isolation of pure IgG.sub.1, and IgG.sub.2a and IgG.sub.2b Immunoglobulins from Mouse Serum Using Proteins A-Sepharose".
Fishwild et al., Clin. Exp. Immunol., 86: 506-513 (1991) "Cytotoxicity Against Human Peripheral Blood Mononuclear Cells and T Cells Lines Mediated By Anti-T Cell Immunotoxins in the Absence of Added Potentiator".
Fishwild et al., Clin. Exp. Immunol., 97: 10-18 (1994) "Characterization of the Increased Cytotoxicity of Gelonin Anti-T Cell Immunoconjugates Compared with Ricin A Immunoconjugates".
Foote et al., J. Mol. Biol., 224: 487-499 (1992) "Antibody Framework Residues Affecting the Conformation of Hypervariable Loops".
Galfre et al., Nature, 266: 550-552 (1977) "Antibodies to Major Histocompatibility Antigens Produced by Hybrid Cell Lines".
Glaser et al., J. Immunol., 149(8): 2607-2614 (1992) "Dissection of the Combining Site in a Humanized Anti-Tac Antibody".
Glockshuber et al., Biochemistry, 29: 1362-1367 (1990) "A Comparison of Strategies to Stabilize Immunoglobulin F.sub.v -Fragments".
Goff et al., Bioconjugate Chem., 1: 381-386 (1990) "Substituted 2-Iminothiolanes: Reagents for the Preparation of Disulfide Cross-Linked Conjugates With Increased Stability".
Goldberg et al., J. Autoimmunity, 4: 617-630 (1991) "Immunological Effects of High Dose Administration of Anti-CD4 Antibody In Rheumatoid Arthritis Patients".
Goldberg et al., Arthritis and Rheumatism, 33: S153, Abstract D115 (1990) "Preliminary Trial of an Anti-CD4 Monoclonal Antibody (MoAb) in Rheumatoid Artritis (RA)".
Gorman et al., Proc. Natl. Acad. Sci. USA, 88: 4181-4185 (1991) "Reshaping a Therapeutic CD4 Antibody".
Hafler et al., Neurology, 36: 777-784 (1986) "Immunologic Responses of Progressive Multiple Sclerosis Patients Treated With An Anti-T-Cell Monoclonal Antibody, Anti-T12".
Hakimi et al., J. Immunol., 147: 1352-1359 (1991) "Reduced Immunogenicity and Improved Pharmacokinetics Of Humanized Anti-Tac in Cynomolgus Monkeys".
Hakimi et al., J. Immunol., 151: 1075 (1993) "Humanized Mik.beta.1, A Humanized Antibody to the IL-2 Receptor .beta.-chain That Acts Synergistically With Humanized Anti-TAC".
Hale et al., The Lancet, 11: 1394-1399 (1988) "Remission Induction in Non-Hodgkin Lymphoma With Reshaped Human Monoclonal Antibody Campath-1H".
Hara et al., Clinical Immunology and Immunopathology, 49: 223-230 (1988) "Stimulatory Effect of CD5 Antibody on B Cells from Patients With Rheumatoid Arthritis".
Harlow et al., Eds., Antibodies: A Laboratory Man
Lucas John
Scheiner Toni R.
Xoma Corporation
LandOfFree
Modified antibody variable domains does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified antibody variable domains, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified antibody variable domains will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-312662